The world is once again hearing the name of a little-known antiviral drug that became globally famous during the COVID-19 pandemic. As reported by Reuters, Britain, scrambling to stay one step ahead of the hantavirus outbreak linked to that ill-fated Antarctic cruise MV Hondius, has just brought in emergency supplies of this antiviral from Japan. It is not a household name, but if you kept up with COVID headlines, Favipiravir probably sounds vaguely familiar. It had a moment during the early pandemic before fading from view, and now, thanks to hantavirus, it is back.
What Is Favipiravir?
Favipiravir has an unusual history. It was developed in Japan by Toyama Chemical, now part of Fujifilm, and sold as Avigan. Japan approved it in 2014 for emergency use against new influenza strains. Unlike antibiotics, which work on bacteria, Favipiravir interferes with the machinery certain viruses use to copy themselves, specifically the RNA polymerase. This makes it a so-called "broad-spectrum" antiviral, best known for showing lab activity against a whole bunch of RNA viruses.
Governments keep an eye on drugs like this for "just in case" situations. During the early days of the COVID-19 pandemic, Favipiravir was hyped in countries like India, Russia, and Japan. It was even given to mild and moderate COVID patients because it came as pills, so hospitalization was not required for intravenous administration. Early hopes were that it would help people recover faster or slow the virus down, but by late 2020, the research was messy. Small studies yielded mixed results. In the end, large reviews concluded that Favipiravir does not significantly lower death rates or prevent severe disease. It is not useless, but it is no medical miracle either.
Why Is the UK Using It for Hantavirus?
The real worry in the current outbreak is the Andes hantavirus strain, which is capable of rare person-to-person spread. When the UK Health Security Agency realized that some Brits could become severely ill, and with no approved drugs for hantavirus, they welcomed extra options. Over the weekend, Japan shipped supplies of Favipiravir as a "just in case" move. The drug is not officially licensed in the UK for this use, but doctors could try it under compassionate or experimental protocols if someone becomes seriously sick.
Evidence for Favipiravir Against Hantavirus
Animal tests suggest that Favipiravir might help against some hantaviruses, and a few scattered human reports add to the hope, but the evidence remains thin. There is no proven antiviral for hantavirus pulmonary syndrome, which can quickly turn deadly, with a 35-40% mortality rate when the Andes virus is involved. Treatment currently relies entirely on supportive care: oxygen, fluids, and extensive hospital monitoring.
Those risks are why Britain moved fast on the import, but Favipiravir is not risk-free. Studies have linked it to birth defects in animals, so it is contraindicated during pregnancy. Doctors also have to monitor for possible liver problems, gout, and stomach upset.
Broader Context: Post-Pandemic Preparedness
The larger context is that the world has changed since COVID-19. Governments are more willing to stockpile experimental antivirals, act quickly, and partner across borders. That is why Japan's supply arrived so fast. These emergency responses are now standard procedure.
For the general public, none of this signals a pandemic, at least not right now. The World Health Organization continues to insist that the risk outside those exposed is very low. The Andes virus has not become easier to catch, and Europe does not have the right rodents to sustain transmission.
Still, the fact that Favipiravir might be back in use is a telling reality of the post-pandemic world: a forgotten cruise, a rare virus, a repurposed COVID drug, and a scramble for life-saving options that nobody saw coming. The WHO assures that the ongoing hantavirus outbreak is not the same as the COVID-19 pandemic, but somehow, here we are — back to using a drug that had its first international moment during COVID.
